Radiation Therapy

Treatment (AI-directed analysis, SBRT) for Lung Cancer

Waitlist Available
Led By Mohamed E Abazeed, MD, PhD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Upup to 5 years
Awards & highlights
No Placebo-Only Group

Study Summary

This trial tests AI to help improve dose prescription for lung radiation therapy to help reduce local recurrence.

Eligible Conditions
  • Lung Cancer
  • Non-Small Cell Lung Cancer


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Local failure free survival (LFS)
Secondary outcome measures
Adherence of the prescribing physician to the dose recommended
Incidence of adverse events
Progression-free survival (PFS)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (AI-directed analysis, SBRT)Experimental Treatment7 Interventions
Patients undergo radiation planning with AI-directed analysis for dose recommendations with Deep Profiler + iGray software on study. Patients then undergo SBRT on study. Patients also undergo PET, CT, MRI, and/or x-ray imaging during screening and follow-up.
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
Completed Phase 2
Stereotactic Body Radiation Therapy
Completed Phase 2
Computed Tomography
Completed Phase 2
Magnetic Resonance Imaging
Completed Phase 3

Find a site

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,529 Previous Clinical Trials
913,291 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,412 Previous Clinical Trials
41,238,996 Total Patients Enrolled
Varian Medical SystemsIndustry Sponsor
52 Previous Clinical Trials
3,551 Total Patients Enrolled
Mohamed E Abazeed, MD, PhDPrincipal Investigator
Northwestern University

Media Library

Stereotactic Body Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05802186 — N/A
Lung Cancer Research Study Groups: Treatment (AI-directed analysis, SBRT)
Lung Cancer Clinical Trial 2023: Stereotactic Body Radiation Therapy Highlights & Side Effects. Trial Name: NCT05802186 — N/A
Stereotactic Body Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05802186 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies for volunteers to join this trial?

"As reported on clinicaltrials.gov, the recruitment for this study has ended as of March 24th 2023. Initially posted on May 31st 2023, this trial is no longer searching for participants; however, there are 6463 other trials that require patients at present time."

Answered by AI

What is the fundamental purpose of this clinical experiment?

"Over a duration of two years, the research team will evaluate this study's primary objective of Overall Survival. Secondary metrics include evaluating Respiratory Function via RTOG Pulmonary Function Test Toxicity Scale, Incidence of Adverse Events through National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0., and assessing physician adherence to prescribed doses as recommended by Deep Profiler +iGray software over one to two weeks during SBRT treatment."

Answered by AI
~47 spots leftby Feb 2025